Green Cross Corp
KRX:006280

Watchlist Manager
Green Cross Corp Logo
Green Cross Corp
KRX:006280
Watchlist
Price: 170 200 KRW 2.1%
Market Cap: 1.9T KRW
Have any thoughts about
Green Cross Corp?
Write Note

Green Cross Corp
Short-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Green Cross Corp
Short-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Green Cross Corp
KRX:006280
Short-Term Debt
â‚©419.3B
CAGR 3-Years
41%
CAGR 5-Years
43%
CAGR 10-Years
13%
Celltrion Inc
KRX:068270
Short-Term Debt
â‚©1.6T
CAGR 3-Years
47%
CAGR 5-Years
41%
CAGR 10-Years
19%
SK Bioscience Co Ltd
KRX:302440
Short-Term Debt
â‚©0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hugel Inc
KOSDAQ:145020
Short-Term Debt
â‚©0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Short-Term Debt
â‚©250m
CAGR 3-Years
-74%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Short-Term Debt
â‚©5B
CAGR 3-Years
21%
CAGR 5-Years
12%
CAGR 10-Years
N/A
No Stocks Found

Green Cross Corp
Glance View

Market Cap
1.9T KRW
Industry
Biotechnology

Green Cross Corporation, rooted in South Korea, has built a formidable presence in the biopharmaceutical industry, primarily focusing on the development and commercialization of vaccines, plasma-derived products, and therapeutic proteins. Founded in 1967, the company initially garnered attention for its innovative efforts in producing hepatitis B vaccines. Over the years, Green Cross expanded its repertoire to include a wide array of biologics. Its operations are vertically integrated, encompassing everything from initial research and development to production and marketing. The company leverages its advanced manufacturing facilities and cutting-edge technology to maintain stringent quality standards and competitive pricing—a strategy that has allowed it to grow both domestically and internationally. A crucial revenue stream for Green Cross arises from its plasma derivatives segment, where the collection and processing of human plasma form the backbone of multiple high-demand medical products, including immunoglobulins, albumin, and clotting factors. Green Cross also benefits from partnerships and collaborations that extend its global footprint, fostering innovation through shared resources and knowledge. Export-driven sales further bolster revenue, as the company taps into growing healthcare needs across various markets around the globe. In essence, Green Cross capitalizes on a meticulous blend of research innovation, quality control, and strategic market expansion, solidifying its role as a key player in the global biopharmaceutical landscape.

Intrinsic Value
216 615.19 KRW
Undervaluation 21%
Intrinsic Value
Price

See Also

What is Green Cross Corp's Short-Term Debt?
Short-Term Debt
419.3B KRW

Based on the financial report for Sep 30, 2024, Green Cross Corp's Short-Term Debt amounts to 419.3B KRW.

What is Green Cross Corp's Short-Term Debt growth rate?
Short-Term Debt CAGR 10Y
13%

Over the last year, the Short-Term Debt growth was 13%. The average annual Short-Term Debt growth rates for Green Cross Corp have been 41% over the past three years , 43% over the past five years , and 13% over the past ten years .

Back to Top